{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:32:30Z","timestamp":1782311550687,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","award":["19K07187"],"award-info":[{"award-number":["19K07187"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research","award":["16H05078"],"award-info":[{"award-number":["16H05078"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31292-8","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T09:02:11Z","timestamp":1766739731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pyridoxamine inhibits dopamine-induced \u03b1-synuclein oligomerization through scavenging neurotoxic dopamine quinone"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-5516","authenticated-orcid":false,"given":"Seon Hwa","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Hatakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3893-0815","authenticated-orcid":false,"given":"Tomoyuki","family":"Oe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"31292_CR1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson\u2019s disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"31292_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3233\/JPD-239005","volume":"13","author":"R Bhidayasiri","year":"2023","unstructured":"Bhidayasiri, R., Kalia, L. V. & Bloem, B. R. Tackling Parkinson\u2019s disease as a global challenge. J. Parkinsons Dis. 13, 1277\u20131280 (2023).","journal-title":"J. Parkinsons Dis."},{"key":"31292_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.plipres.2010.05.004","volume":"49","author":"V Ruip\u00e9rez","year":"2010","unstructured":"Ruip\u00e9rez, V., Darios, F. & Davletov, B. Alpha-synuclein, lipids and Parkinson\u2019s disease. Prog Lipid Res. 49, 420\u2013428 (2010).","journal-title":"Prog Lipid Res."},{"key":"31292_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mcn.2013.01.004","volume":"54","author":"W Xiang","year":"2013","unstructured":"Xiang, W. et al. Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol. Cell. Neurosci. 54, 71\u201383 (2013).","journal-title":"Mol. Cell. Neurosci."},{"key":"31292_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13731","volume":"139","author":"A Bose","year":"2016","unstructured":"Bose, A. & Beal, M. F. Mitochondrial dysfunction in Parkinson\u2019s disease. J. Neurochem. 139, 216\u2013231 (2016).","journal-title":"J. Neurochem"},{"key":"31292_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s12264-022-00899-6","volume":"38","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Calcium homeostasis in Parkinson\u2019s disease: From pathology to treatment. Neurosci. Bull. 38, 1267\u20131270 (2022).","journal-title":"Neurosci. Bull."},{"key":"31292_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fneur.2018.00295","volume":"9","author":"V. Ghiglieri","year":"2018","unstructured":"Ghiglieri, V., Calabrese, V. & Calabresi, P. Alpha-synuclein: From early synaptic dysfunction to neurodegeneration. Front. Neurol. 9, 295 (2018).","journal-title":"Front. Neurol."},{"key":"31292_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"D Charvin","year":"2018","unstructured":"Charvin, D., Medori, R., Hauser, R. A. & Rascol, O. Therapeutic strategies for Parkinson\u2019s disease: Beyond dopaminergic drugs. Nat. Rev. Drug Discov. 17, 804\u2013822 (2018).","journal-title":"Nat. Rev. Drug Discov"},{"key":"31292_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/cells10040735","volume":"10","author":"L. Di Speranza","year":"2021","unstructured":"Speranza, L., Di Porzio, U., Viggiano, D., de Donato, A. & Volpicelli, F. Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control. Cells 10, 735 (2021).","journal-title":"Cell"},{"key":"31292_CR10","doi-asserted-by":"publisher","first-page":"11080","DOI":"10.1016\/S0021-9258(18)60929-9","volume":"262","author":"B Kalyanaraman","year":"1987","unstructured":"Kalyanaraman, B., Premovic, P. I. & Sealy, R. C. Semiquinone anion radicals from addition of amino acids, peptides, and proteins to quinones derived from oxidation of catechols and catecholamines. An ESR spin stabilization study. J. Biol. Chem. 262, 11080\u201311087 (1987).","journal-title":"J. Biol. Chem."},{"key":"31292_CR11","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.freeradbiomed.2006.07.009","volume":"41","author":"O Terland","year":"2006","unstructured":"Terland, O., Alm\u00e5s, B., Flatmark, T., Andersson, K. K. & S\u00f8rlie, M. One-electron oxidation of catecholamines generates free radicals with an in vitro toxicity correlating with their lifetime. Free Radic Biol. Med. 41, 1266\u20131271 (2006).","journal-title":"Free Radic Biol. Med."},{"key":"31292_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nrn983","volume":"3","author":"J Lotharius","year":"2002","unstructured":"Lotharius, J. & Brundin, P. Pathogenesis of Parkinson\u2019s disease: Dopamine, vesicles and \u03b1-synuclein. Nat. Rev. Neurosci. 3, 932\u2013942 (2002).","journal-title":"Nat. Rev. Neurosci."},{"key":"31292_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0026-895X(25)13535-9","volume":"14","author":"DG Graham","year":"1978","unstructured":"Graham, D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633\u2013643 (1978).","journal-title":"Mol. Pharmacol."},{"key":"31292_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1046\/j.1471-4159.2001.00243.x","volume":"77","author":"I Paris","year":"2001","unstructured":"Paris, I. et al. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J. Neurochem. 77, 519\u2013529 (2001).","journal-title":"J. Neurochem"},{"key":"31292_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1021\/tx0497144","volume":"18","author":"I Paris","year":"2005","unstructured":"Paris, I. et al. Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem. Res. Toxicol. 18, 415\u2013419 (2005).","journal-title":"Chem. Res. Toxicol."},{"key":"31292_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1021\/tx960052v","volume":"9","author":"XM Shen","year":"1996","unstructured":"Shen, X. M., Xia, B., Wrona, M. Z. & Dryhurst, G. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: Possible metabolites of relevance to Parkinson\u2019s disease. Chem. Res. Toxicol. 9, 1117\u20131126 (1996).","journal-title":"Chem. Res. Toxicol."},{"key":"31292_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.neuint.2006.01.023","volume":"49","author":"L Mosca","year":"2006","unstructured":"Mosca, L. et al. 5-S-Cysteinyl-dopamine effect on the human dopaminergic neuroblastoma cell line SH-SY5Y. Neurochem Int. 49, 262\u2013269 (2006).","journal-title":"Neurochem Int."},{"key":"31292_CR18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1046\/j.1471-4159.2001.00125.x","volume":"76","author":"RE Whitehead","year":"2001","unstructured":"Whitehead, R. E., Ferrer, J. V., Javitch, J. A. & Justice, J. B. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 76, 1242\u20131251 (2001).","journal-title":"J. Neurochem"},{"key":"31292_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0038026","volume":"7","author":"E Belluzzi","year":"2012","unstructured":"Belluzzi, E. et al. Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: Possible implications for Parkinson\u2019s disease. PLoS One. 7, 1\u20139 (2012).","journal-title":"PLoS One"},{"key":"31292_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1126\/science.aam9080","volume":"357","author":"LF Burbulla","year":"2017","unstructured":"Burbulla, L. F. et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease. Sci.\u00a0357, 1255\u20131261 (2017).","journal-title":"Sci. (80-)"},{"key":"31292_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1126\/science.1063522","volume":"294","author":"KA Conway","year":"2001","unstructured":"Conway, K. A., Rochet, J. C., Bieganski, R. M. & Lansbury, J. Kinetic stabilization of the \u03b1-synuclein protofibril by a dopamine-\u03b1-synuclein adduct. Sci.\u00a0294, 1346\u20131349 (2001).","journal-title":"Sci. (80-)"},{"key":"31292_CR22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/nn.4641","volume":"20","author":"DE Mor","year":"2017","unstructured":"Mor, D. E. et al. Dopamine induces soluble \u03b1-synuclein oligomers and nigrostriatal degeneration. Nat. Neurosci. 20, 1560\u20131568 (2017).","journal-title":"Nat. Neurosci."},{"key":"31292_CR23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00018-005-5082-7","volume":"62","author":"PA Voziyan","year":"2005","unstructured":"Voziyan, P. A. & Hudson, B. G. Pyridoxamine as a multifunctional pharmaceutical: Targeting pathogenic glycation and oxidative damage. Cell. Mol. Life Sci. 62, 1671\u20131681 (2005).","journal-title":"Cell. Mol. Life Sci."},{"key":"31292_CR24","doi-asserted-by":"publisher","first-page":"21177","DOI":"10.1074\/jbc.M003263200","volume":"275","author":"JM Onorato","year":"2000","unstructured":"Onorato, J. M., Jenkins, A. J., Thorpe, S. R. & Baynes, J. W. Pyridoxamine, an inhibitor of advanced glycation reactions, inhibits advanced lipoxidation reactions: mechanism of action of pyridoxamine. J. Biol. Chem. 275, 21177\u201321184 (2000).","journal-title":"J. Biol. Chem."},{"key":"31292_CR25","doi-asserted-by":"publisher","first-page":"42012","DOI":"10.1074\/jbc.M304292200","volume":"278","author":"TO Metz","year":"2003","unstructured":"Metz, T. O., Alderson, N. L., Chachich, M. E., Thorpe, S. R. & Baynes, J. W. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: Evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J. Biol. Chem. 278, 42012\u201342019 (2003).","journal-title":"J. Biol. Chem."},{"key":"31292_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0003-9861(02)00067-X","volume":"402","author":"RH Nagaraj","year":"2002","unstructured":"Nagaraj, R. H. et al. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: Characterization of a major product from the reaction of pyridoxamine and Methylglyoxal. Arch. Biochem. Biophys. 402, 110\u2013119 (2002).","journal-title":"Arch. Biochem. Biophys."},{"key":"31292_CR27","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1074\/jbc.M109935200","volume":"277","author":"PA Voziyan","year":"2002","unstructured":"Voziyan, P. A., Metz, T. O., Baynes, J. W. & Hudson, B. G. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277, 3397\u20133403 (2002).","journal-title":"J. Biol. Chem."},{"key":"31292_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00726-005-0209-6","volume":"30","author":"Z Kang","year":"2006","unstructured":"Kang, Z., Li, H., Li, G. & Yin, D. Reaction of pyridoxamine with malondialdehyde: Mechanism of inhibition of formation of advanced lipoxidation end-products. Amino Acids. 30, 55\u201361 (2006).","journal-title":"Amino Acids"},{"key":"31292_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1021\/tx0300535","volume":"17","author":"V Amarnath","year":"2004","unstructured":"Amarnath, V., Amarnath, K., Amarnath, K., Davies, S. & Roberts, L. J. Pyridoxamine: An extremely potent scavenger of 1,4-dicarbonyls. Chem. Res. Toxicol. 17, 410\u2013415 (2004).","journal-title":"Chem. Res. Toxicol."},{"key":"31292_CR30","doi-asserted-by":"publisher","first-page":"15756","DOI":"10.1021\/bi061860g","volume":"45","author":"SS Davies","year":"2006","unstructured":"Davies, S. S. et al. Pyridoxamine analogues scavenge lipid-derived \u03b3-ketoaldehydes and protect against H2O2-mediated cytotoxicity. Biochemistry 45, 15756\u201315767 (2006).","journal-title":"Biochemistry"},{"key":"31292_CR31","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1021\/acs.chemrestox.5b00301","volume":"28","author":"V Amarnath","year":"2015","unstructured":"Amarnath, V. & Amarnath, K. Scavenging 4-oxo-2-nonenal. Chem. Res. Toxicol. 28, 1888\u20131890 (2015).","journal-title":"Chem. Res. Toxicol."},{"key":"31292_CR32","first-page":"1","volume":"13","author":"SH Lee","year":"2018","unstructured":"Lee, S. H., Matsunaga, A. & Oe, T. Inhibition effect of pyridoxamine on lipid hydroperoxide-derived modifications to human serum albumin. PLoS One. 13, 1\u201323 (2018).","journal-title":"PLoS One"},{"key":"31292_CR33","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1126\/science.1059501","volume":"292","author":"SH Lee","year":"2001","unstructured":"Lee, S. H., Oe, T. & Blair, I. A. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Sci.\u00a0292, 2083\u20132086 (2001).","journal-title":"Sci. (80-)"},{"key":"31292_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/03602530600959508","volume":"38","author":"LM Sayre","year":"2006","unstructured":"Sayre, L. M., Lin, D., Yuan, Q., Zhu, X. & Tang, X. Protein adducts generated from products of lipid oxidation: Focus on HNE and ONE. Drug Metab. Rev. 38, 651\u2013675 (2006).","journal-title":"Drug Metab. Rev."},{"key":"31292_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s43188-022-00155-z","volume":"39","author":"SH Lee","year":"2023","unstructured":"Lee, S. H., Tsutsui, M., Matsunaga, A. & Oe, T. Lipid hydroperoxide-derived insulin resistance and its inhibition by pyridoxamine in skeletal muscle cells. Toxicol. Res. 39, 147\u2013156 (2023).","journal-title":"Toxicol. Res."},{"key":"31292_CR36","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.1002\/anie.201811122","volume":"58","author":"E Monzani","year":"2019","unstructured":"Monzani, E. et al. Oxidative stress and protein-quinone modifications in Parkinson\u2019s and other neurodegenerative diseases. Angew Chemie - Int. Ed. 58, 6512\u20136527 (2019).","journal-title":"Angew Chemie - Int. Ed."},{"key":"31292_CR37","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/acs.chemrestox.2c00193","volume":"35","author":"AK Hurben","year":"2022","unstructured":"Hurben, A. K. & Tretyakova, N. Y. Role of protein damage inflicted by dopamine metabolites in Parkinson\u2019s disease: Evidence, tools, and outlook. Chem. Res. Toxicol. 35, 1789\u20131804 (2022).","journal-title":"Chem. Res. Toxicol."},{"key":"31292_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1021\/jo982019e","volume":"64","author":"A Yokoyama","year":"1999","unstructured":"Yokoyama, A., Ohwada, T. & Shudo, K. Prototype Pictet-Spengler reactions catalyzed by superacids. Involvement of dicationic superelectrophiles. J. Org. Chem. 64, 611\u2013617 (1999).","journal-title":"J. Org. Chem."},{"key":"31292_CR39","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1046\/j.1471-4159.1995.64020919.x","volume":"64","author":"TG Hastings","year":"1995","unstructured":"Hastings, T. G. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J. Neurochem. 64, 919\u2013924 (1995).","journal-title":"J. Neurochem"},{"key":"31292_CR40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0304-4165(96)00093-1","volume":"1334","author":"C Foppoli","year":"1997","unstructured":"Foppoli, C., Coccia, R., Cini, C. & Rosei, M. A. Catecholamines oxidation by xanthine oxidase. Biochim. Biophys. Acta - Gen. Subj. 1334, 200\u2013206 (1997).","journal-title":"Biochim. Biophys. Acta - Gen. Subj."},{"key":"31292_CR41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1006\/bbrc.1994.1454","volume":"200","author":"MA Rosei","year":"1994","unstructured":"Rosei, M. A., Blarzino, C., Foppoli, C., Mosca, L. & Coccia, R. Lipoxygenase-catalyzed oxidation of catecholamines. Biochem. Biophys. Res. Commun. 200, 344\u2013350 (1994).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"31292_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0753-3322(03)00043-X","volume":"57","author":"DM Townsend","year":"2003","unstructured":"Townsend, D. M., Tew, K. D. & Tapiero, H. The importance of glutathione in human disease. Biomed. Pharmacother. 57, 145\u2013155 (2003).","journal-title":"Biomed. Pharmacother"},{"key":"31292_CR43","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2174\/138920006779010601","volume":"7","author":"I Blair","year":"2006","unstructured":"Blair, I. Endogenous glutathione adducts. Curr. Drug Metab. 7, 853\u2013872 (2006).","journal-title":"Curr. Drug Metab."},{"key":"31292_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF03033137","volume":"5","author":"M Asanuma","year":"2003","unstructured":"Asanuma, M., Miyazaki, I. & Ogawa, N. Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson\u2019s disease. Neurotox. Res. 5, 165\u2013176 (2003).","journal-title":"Neurotox. Res."},{"key":"31292_CR45","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1096\/fj.08-125443","volume":"23","author":"HL Martin","year":"2009","unstructured":"Martin, H. L. & Teismann, P. Glutathione-a review on its role and significance in Parkinson\u2019s disease. FASEB J. 23, 3263\u20133272 (2009).","journal-title":"FASEB J."},{"key":"31292_CR46","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1111\/j.1742-4658.2005.04792.x","volume":"272","author":"HT Li","year":"2005","unstructured":"Li, H. T. et al. Inhibition of \u03b1-synuclein fibrillization by dopamine analogs via reaction with the amino groups of \u03b1-synuclein: Implication for dopaminergic neurodegeneration. FEBS J. 272, 3661\u20133672 (2005).","journal-title":"FEBS J."},{"key":"31292_CR47","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.bbrc.2010.03.044","volume":"394","author":"M Bisaglia","year":"2010","unstructured":"Bisaglia, M. et al. Dopamine quinones interact with \u03b1-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 394, 424\u2013428 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"31292_CR48","doi-asserted-by":"publisher","first-page":"e55068","DOI":"10.1371\/journal.pone.0055068","volume":"8","author":"K Nakaso","year":"2013","unstructured":"Nakaso, K. et al. Dopamine-mediated oxidation of methionine 127 in \u03b1-synuclein causes cytotoxicity and oligomerization of \u03b1-synuclein. PLoS One 8, e55068 (2013).","journal-title":"PLoS One"},{"key":"31292_CR49","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1074\/jbc.RA118.001907","volume":"294","author":"E Ponzini","year":"2019","unstructured":"Ponzini, E. et al. Methionine oxidation in \u03b1-synuclein inhibits its propensity for ordered secondary structure. J. Biol. Chem. 294, 5657\u20135665 (2019).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31292-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31292-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31292-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:02:42Z","timestamp":1770040962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31292-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31292"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31292-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6478169\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The original version of this Article contained errors in the Reference list, where Reference 16 was incorrectly listed as Reference 43. Consequently, the references have been renumbered. The original Article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1790"}}